Biotronik’s Orsiro drug-eluting stent tops Abbott’s Xience in study

Biotronik said today that its Orsiro drug-eluting stent beat Abbott‘s (NYSE:ABT) Xience DES in a trial comparing the target lesion failure rates of both devices.

The data, which were presented at the European Society of Cardiology’s ESC Congress and published by The Lancet, showed a 6.2% TLF rate at 12-months for patients treated with Orsiro compared to 9.6% for patients treated with Xience.

Get the full story at our sister site, Drug Delivery Business News.

The post Biotronik’s Orsiro drug-eluting stent tops Abbott’s Xience in study appeared first on MassDevice.

from MassDevice http://ift.tt/2gkhgSD